Log in
Watch fullscreen
2 years ago

Oxford's COVID-19 vaccine shows promising immune response in human trials

Arirang News
Arirang News
코로나19 백신 "모든 투약자 면역 반응 생성"...글로벌 혈장치료 임상도 40배 늘어

Some promising signs of vaccines and treatments for COVID-19 are emerging.
Scientists at Oxford University in the U.K. say their experimental vaccine has led to an immune response in everybody who got the shot.
Clinical trials of treatments that use the plasma of recovered COVID-19 patients are also on the rise.
Choi Jeong-yoon reports.
A potential COVID-19 vaccine developed by Oxford University has reportedly produced a promising immune response in a large, early-stage human trial.
According to data published Monday in the medical journal, The Lancet,... 100 percent of some 1-thousand participants in the trial developed antibodies.
Jointly developed with pharmaceutical giant AstraZeneca, the vaccine also produced killer T-cells that help patients combat the infection by attacking the infected cells.
The World Health Organization welcomed the news,... but warned that there's a long road ahead.
"Effectively, we have 23 COVID-19 candidate vaccines in clinical development. And as of today, we add one candidate vaccine for which phase one clinical data is available...But again, there is a long way to go. These are phase one studies. We now need to move into larger scale, real world trials."
Other vaccine developers also had positive news, with America's Pfizer and Germany's BioNTech successfully immunizing their 60 participants.
Pfizer and BioNTech now plan to begin testing on some 30-thousand volunteers this month to prove the efficacy of their vaccine.
Human trials on treatments for the virus are also accelerating.
The effects of treatments like Remdesivir and hydroxychloroquine remain uncertain and are only reported to work on limited groups,... but a convalescent plasma therapeutic which uses COVID-19 antibodies extracted from recovered patients is on the rise as an alternative.
A website by the U.S. National Institutes of Health that tracks clinical trials in action shows the number of clinical trials for a plasma treatment increased to around 120 in July.
That's up from just 3 trials in March.
But while its considered one of the most practical treatments for the virus,...ramping up collection of the plasma is proving a challenge.
Choi Jeong-yoon, Arirang News.